Table 6.
TRAEs during treatment in both groups.
| Clinic features | All grades of TRAEs | P value | Grade 3–4 of TRAEs | P value | ||
|---|---|---|---|---|---|---|
| cTACEn = 31 | No-cTACEn = 23 | cTACEn = 31 | No-cTACEn = 23 | |||
| Leucopenia | 7 (22.6%) | 3 (13.0%) | 0.591 | 1 (3.2%) | 0 (0.0%) | 1.000 |
| Thrombocytopenia | 15 (48.4%) | 13 (56.5%) | 0.554 | 0 (0.0%) | 0 (0.0%) | --- |
| Lymphopenia | 24 (77.4%) | 12 (52.2%) | 0.052 | 4 (12.9%) | 3 (13.0%) | 1.000 |
| Anemia | 13 (41.9%) | 11 (47.8%) | 0.667 | 0 (0.0%) | 0 (0.0%) | --- |
| Elevated ALT | 27 (87.1%) | 7 (30.4%) | 0.000* | 4 (12.9%) | 2 (8.7%) | 0.961 |
| Elevated AST | 31 (100.0%) | 18 (78.3%) | 0.024* | 2 (6.5%) | 3 (13.0%) | 0.725 |
| Elevated GGT | 29 (93.5%) | 18 (78.3%) | 0.213 | 4 (12.9%) | 3 (13.0%) | 1.000 |
| Elevated TBIL | 20 (64.5%) | 9 (39.1%) | 0.064 | 0 (0.0%) | 2 (8.7%) | 0.345 |
| Hypothyroidism | 10 (32.3%) | 8 (34.8%) | 0.846 | 2 (6.5%) | 2 (8.7%) | 1.000 |
| Hand-foot syndrome | 15 (48.4%) | 12 (52.2%) | 0.783 | 3 (9.7%) | 2 (8.7%) | 1.000 |
| Rash | 18 (58.1%) | 8 (34.8%) | 0.090 | 1(3.2%) | 1 (4.3%) | 1.000 |
| RCCEP | 3 (9.7%) | 2 (8.7%) | 1.000 | 0 (0.0%) | 0 (0.0%) | --- |
| Urine protein | 5 (16.1%) | 3 (13.0%) | 1.000 | 0 (0.0%) | 0 (0.0%) | --- |
| Muscle soreness | 3 (9.7%) | 3 (13.0%) | 1.000 | 0 (0.0%) | 0 (0.0%) | --- |
| Diarrhea | 7 (22.6%) | 5 (21.7%) | 0.941 | 0 (0.0%) | 0 (0.0%) | --- |
| Poor appetite | 10 (32.3%) | 4 (17.4%) | 0.358 | 0 (0.0%) | 0 (0.0%) | --- |
| Gingival bleeding | 4 (12.9%) | 3 (13.0%) | 1.000 | 0 (0.0%) | 0 (0.0%) | --- |
*p< 0.05.
ALT, alanine aminotransferase; AST, aspartic aminotransferase; GGT, γ- glutamyl transpeptidase; TBIL, total bilirubin; RCCEP, reactive cutaneous capillary endothelial proliferation.